The nation of Zimbabwe has turned down a significant American health deal valued at 367 million US dollars (£272m) spanning five years due to Washington's request for confidential information.
This rejection was revealed after a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesman later clarified that the United States was seeking genetic material for research and profit while was not willing to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more talks to secure a agreement acceptable to both sides so the country's vital HIV programme can proceed.
Broader Background
This rejection comes after a similar case in Kenya, where a court halted a related deal with the US after legal challenges were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and accountability.
As per statements, Sixteen nations in Africa have to date signed similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research without any assurance that the final treatments would be accessible to our citizens should a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining systems already set up via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This framework is intended to guarantee that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We are open to further discussions with our American counterparts on how subsequent collaboration could be arranged in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that talks must proceed given that a large portion of the country's Aids initiatives relied on international support.
"Where specific concerns arise, including those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
The situation highlights the complex debate between receiving vital international aid and protecting local interests in an increasingly interconnected world.